spinosin: isolated from seeds of Ziziph spinosa; structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
spinosin : A flavone C-glycoside that is flavone substituted by hydroxy groups at positions 5 and 4', a methoxy group at position 7 and a 2-O-beta-D-glucopyranosyl-beta-D-glucopyranosyl residue at position 6 via a C-glycosidic linkage. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]
ID Source | ID |
---|---|
PubMed CID | 155692 |
CHEBI ID | 81360 |
SCHEMBL ID | 2980651 |
MeSH ID | M0156600 |
Synonym |
---|
spinosin |
6-[(2s,3r,4s,5s,6r)-4,5-dihydroxy-6-(hydroxymethyl)-3-[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxan-2-yl]-5-hydroxy-2-(4-hydroxyphenyl)-7-methoxychromen-4-one |
72063-39-9 |
C17834 |
6-(2-o-beta-d-glucopyranosyl-beta-d-glucopyranosyl)-5-hydroxy-2-(4-hydroxyphenyl)-7-methoxy-4h-1-benzopyran-4-one |
4h-1-benzopyran-4-one, 6-(2-o-beta-d-glucopyranosyl-beta-d-glucopyranosyl)-5-hydroxy-2-(4-hydroxyphenyl)-7-methoxy- |
S9134 |
AKOS015897169 |
SCHEMBL2980651 |
(1s)-1,5-anhydro-2-o-beta-d-glucopyranosyl-1-[5-hydroxy-2-(4-hydroxyphenyl)-7-methoxy-4-oxo-4h-1-benzopyran-6-yl]-d-glucitol |
flavoayamenin |
2''-o-glycosylswertisin |
CHEBI:81360 |
DTXSID50222396 |
Q-100793 |
AC-31296 |
mfcd09754430 |
Q27155298 |
HY-N0651 |
6-((2s,3r,4s,5s,6r)-4,5-dihydroxy-6-(hydroxymethyl)-3-(((2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)tetrahydro-2h-pyran-2-yl)oxy)tetrahydro-2h-pyran-2-yl)-5-hydroxy-2-(4-hydroxyphenyl)-7-methoxy-4h-chromen-4-one |
BS-17968 |
HMS3886F18 |
CCG-270216 |
CS-0009676 |
A866326 |
P2887 |
Spinosin is a C-glycoside flavonoid isolated from the seeds of Zizyphus jujuba var.
Excerpt | Reference | Relevance |
---|---|---|
"Spinosin is a C-glycoside flavonoid isolated from the seeds of Zizyphus jujuba var. " | ( Ameliorating effect of spinosin, a C-glycoside flavonoid, on scopolamine-induced memory impairment in mice. Ahn, YJ; Jang, DS; Jo, YW; Jung, IH; Kang, SS; Kim, JS; Kwon, G; Lee, HE; Lee, SY; Park, SJ; Ryu, JH; Woo, H, 2014) | 2.16 |
Excerpt | Reference | Relevance |
---|---|---|
"Treatments of spinosin and 6'''‑feruloylspinosin led to the reduction of glycogen synthase kinase‑3β (GSK3β) phosphorylation at Tyr216, and the increase of peroxisome proliferator‑activated receptor γ coactivator (PGC)‑1α and its downstream signaling proteins, including nuclear factor (erythroid‑derived 2)‑like 2 (Nrf2) and hemeoxygenase1 (HO‑1)." | ( Spinosin and 6'''‑Feruloylspinosin protect the heart against acute myocardial ischemia and reperfusion in rats. Cheng, S; Gu, M; Gu, Y; He, P; Jia, Y; Liu, X; Lyu, C; Xu, Y, 2019) | 2.3 |
Excerpt | Reference | Relevance |
---|---|---|
" The main pharmacokinetic parameters T(0." | ( Pharmacokinetics and tissue distribution of spinosin after intravenous administration in rats. Dai, YH; Deng, YL; Li, Y; Li, YJ; Yu, YL, 2007) | 0.6 |
" The validated method has been successfully applied to comparing pharmacokinetic profiles of analytes in rat plasma." | ( A UFLC-MS/MS method for simultaneous quantitation of spinosin, mangiferin and ferulic acid in rat plasma: application to a comparative pharmacokinetic study in normal and insomnic rats. Bi, K; Chen, X; He, B; Jia, Y; Li, Q; Lv, C; Xiao, F; Xu, H; Zhao, L, 2012) | 0.63 |
"To study the pharmacokinetic effect of different combined administration with monarch drug Ziziphi Spinosae Semen on its main components in rats." | ( [Pharmacokinetic effect of combined administration on spinosin and ferulic acid in monarch drug Ziziphi Spinosae Semen kernel]. Chen, XJ; Fang, MF; Gao, R; Li, S; Wang, SX; Wang, XF, 2015) | 0.67 |
Excerpt | Reference | Relevance |
---|---|---|
"The results showed that the absorption rate constant (0." | ( The preparation and investigation of spinosin-phospholipid complex self-microemulsifying drug delivery system based on the absorption characteristics of spinosin. Lai, C; Song, P; Xie, J; Zhang, Y, 2019) | 0.79 |
Excerpt | Relevance | Reference |
---|---|---|
"The aim of this research was to investigate the intestinal absorption characteristics and mechanisms of spinosin (SPI), and a new dosage form was prepared to increase the intestinal absorption of SPI." | ( The preparation and investigation of spinosin-phospholipid complex self-microemulsifying drug delivery system based on the absorption characteristics of spinosin. Lai, C; Song, P; Xie, J; Zhang, Y, 2019) | 1 |
Role | Description |
---|---|
plant metabolite | Any eukaryotic metabolite produced during a metabolic reaction in plants, the kingdom that include flowering plants, conifers and other gymnosperms. |
anxiolytic drug | Anxiolytic drugs are agents that alleviate anxiety, tension, and anxiety disorders, promote sedation, and have a calming effect without affecting clarity of consciousness or neurologic conditions. |
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] |
Class | Description |
---|---|
flavone C-glycoside | Any C-glycosyl compound arising formally from the elimination of water from a glycosidic hydroxy group and an H atom bound to a flavone skeleton, thus creating a C-C bond. |
dihydroxyflavone | Any hydroxyflavone in which two ring hydrogens are replaced by hydroxy substituents. |
monomethoxyflavone | Any methoxyflavone with a single methoxy substituent. |
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] |
Timeframe | Studies, This Drug (%) | All Drugs % |
---|---|---|
pre-1990 | 1 (2.56) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 7 (17.95) | 29.6817 |
2010's | 22 (56.41) | 24.3611 |
2020's | 9 (23.08) | 2.80 |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.
| This Compound (32.25) All Compounds (24.57) |
Publication Type | This drug (%) | All Drugs (%) |
---|---|---|
Trials | 0 (0.00%) | 5.53% |
Reviews | 0 (0.00%) | 6.00% |
Case Studies | 0 (0.00%) | 4.05% |
Observational | 0 (0.00%) | 0.25% |
Other | 39 (100.00%) | 84.16% |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |